

Eps8L3 siRNA (h): sc-88663

BACKGROUND

Eps8L3 (epidermal growth factor receptor kinase substrate 8-like protein 3), also known as EPS8R3, is a 593 amino acid protein that is related to Eps8, a novel EGF receptor substrate. Eps8L3 is a cytoplasmic protein that is part of a complex that contains Sos 1, Abi-1 and Eps8L2. Eps8L3 contains one SH3 domain, and has been found to interact with Abi-1 and FAS-L. Eps8L3 is expressed as three isoforms produced by alternative splicing and is encoded by a gene mapping to human chromosome 1p13.3. Human chromosome 1 spans 260 million base pairs, contains over 3,000 genes, comprises nearly 8% of the human genome and houses a large number of disease-associated genes, including those that are involved in familial adenomatous polyposis, Stickler syndrome, Parkinson's disease, Gaucher disease, schizophrenia and Usher syndrome.

REFERENCES

1. Eudy, J.D., Yao, S., Weston, M.D., Ma-Edmonds, M., Talmadge, C.B., Cheng, J.J., Kimberling, W.J. and Sumegi, J. 1998. Isolation of a gene encoding a novel member of the nuclear receptor superfamily from the critical region of Usher syndrome type IIa at 1q41. *Genomics* 50: 382-384.
2. Tayebi, N., Callahan, M., Madike, V., Stubblefield, B.K., Orvisky, E., Krasnewich, D., Fillano, J.J. and Sidransky, E. 2001. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. *Mol. Genet. Metab.* 73: 313-321.
3. Tocchetti, A., Confalonieri, S., Scita, G., Di Fiore, P.P. and Betsholtz, C. 2003. In silico analysis of the EPS8 gene family: genomic organization, expression profile, and protein structure. *Genomics* 81: 234-244.
4. Plasilova, M., Russell, A.M., Wanner, A., Wolf, A., Dobbie, Z., Müller, H.J. and Heinemann, K. 2004. Exclusion of an extracolonic disease modifier locus on chromosome 1p33-36 in a large Swiss familial adenomatous polyposis kindred. *Eur. J. Hum. Genet.* 12: 365-371.
5. Offenhäuser, N., Borgonovo, A., Disanza, A., Romano, P., Ponzanelli, I., Iannolo, G., Di Fiore, P.P. and Scita, G. 2004. The eps8 family of proteins links growth factor stimulation to Actin reorganization generating functional redundancy in the Ras/Rac pathway. *Mol. Biol. Cell* 15: 91-98.
6. Wang, A.G., Yoon, S.Y., Oh, J.H., Jeon, Y.J., Kim, M., Kim, J.M., Byun, S.S., Yang, J.O., Kim, J.H., Kim, D.G., Yeom, Y.I., Yoo, H.S., Kim, Y.S. and Kim, N.S. 2006. Identification of intrahepatic cholangiocarcinoma related genes by comparison with normal liver tissues using expressed sequence tags. *Biochem. Biophys. Res. Commun.* 345: 1022-1032.
7. Betarbet, R., Anderson, L.R., Gearing, M., Hodges, T.R., Fritz, J.J., Lah, J.J. and Levey, A.I. 2008. Fas-associated factor 1 and Parkinson's disease. *Neurobiol. Dis.* 31: 309-315.
8. Voss, M., Lettau, M. and Janssen, O. 2009. Identification of SH3 domain interaction partners of human FasL (CD178) by phage display screening. *BMC Immunol.* 10: 53.
9. Yokoi, T., Koide, R., Matsuoka, K., Nakagawa, A. and Azuma, N. 2009. Analysis of the vitreous membrane in a case of type 1 Stickler syndrome. *Graefes Arch. Clin. Exp. Ophthalmol.* 247: 715-718.

CHROMOSOMAL LOCATION

Genetic locus: EPS8L3 (human) mapping to 1p13.3.

PRODUCT

Eps8L3 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see Eps8L3 shRNA Plasmid (h): sc-88663-SH and Eps8L3 shRNA (h) Lentiviral Particles: sc-88663-V as alternate gene silencing products.

For independent verification of Eps8L3 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-88663A, sc-88663B and sc-88663C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

Eps8L3 siRNA (h) is recommended for the inhibition of Eps8L3 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor Eps8L3 gene expression knockdown using RT-PCR Primer: Eps8L3 (h)-PR: sc-88663-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.